Fractional allelic loss in non–end-stage cirrhosis: Correlations with hepatocellular carcinoma development during follow-up
Corresponding Author
Massimo Roncalli M.D., Ph.D.
Departments of Pathology and Research Laboratories, Humanitas Clinical Institute of Rozzano, Milan
University of Milan
Department of Pathology, University of Milan School of Medicine, Humanitas Clinical Institute, Via Manzoni 56, 20089 Rozzano (Milano), Italy. fax: (39) 0282244791===Search for more papers by this authorPaolo Bianchi
Departments of Pathology and Research Laboratories, Humanitas Clinical Institute of Rozzano, Milan
Search for more papers by this authorGiorgia Ceva Grimaldi
Departments of Pathology and Research Laboratories, Humanitas Clinical Institute of Rozzano, Milan
Search for more papers by this authorDaniele Ricci
Departments of Pathology and Research Laboratories, Humanitas Clinical Institute of Rozzano, Milan
Search for more papers by this authorLuigi Laghi
Departments of Pathology and Research Laboratories, Humanitas Clinical Institute of Rozzano, Milan
Search for more papers by this authorEnrico Opocher
Department of Surgery, San Paolo Hospital of Milan
Search for more papers by this authorMauro Borzio
Department of Medicine, Fatebenefratelli Hospital of Milan, Italy
Search for more papers by this authorCorresponding Author
Massimo Roncalli M.D., Ph.D.
Departments of Pathology and Research Laboratories, Humanitas Clinical Institute of Rozzano, Milan
University of Milan
Department of Pathology, University of Milan School of Medicine, Humanitas Clinical Institute, Via Manzoni 56, 20089 Rozzano (Milano), Italy. fax: (39) 0282244791===Search for more papers by this authorPaolo Bianchi
Departments of Pathology and Research Laboratories, Humanitas Clinical Institute of Rozzano, Milan
Search for more papers by this authorGiorgia Ceva Grimaldi
Departments of Pathology and Research Laboratories, Humanitas Clinical Institute of Rozzano, Milan
Search for more papers by this authorDaniele Ricci
Departments of Pathology and Research Laboratories, Humanitas Clinical Institute of Rozzano, Milan
Search for more papers by this authorLuigi Laghi
Departments of Pathology and Research Laboratories, Humanitas Clinical Institute of Rozzano, Milan
Search for more papers by this authorEnrico Opocher
Department of Surgery, San Paolo Hospital of Milan
Search for more papers by this authorMauro Borzio
Department of Medicine, Fatebenefratelli Hospital of Milan, Italy
Search for more papers by this authorAbstract
Hepatocellular carcinoma (HCC) is usually preceded by cirrhosis whose genetic background is still poorly understood. The aim of this study was to evaluate, in non–end-stage cirrhosis, the fractional allelic loss (FAL) at loci mostly reported to be altered in HCC and the microsatellite instability (MSI). Twenty cases of cirrhosis were retrospectively selected. Eleven had developed an HCC during the follow-up (HCC-prone group), while 9 remained HCC-free (HCC-free group). Microdissected hepatocellular cirrhotic nodules from basal liver biopsies, were studied at 20 loci (on the chromosomal arms 1p and 1q, 3p, 4q, 6q, 7q, 8p, 13q, and 18q) and with the mononucleotide repeats BAT26andTGFbIIR. Genetic changes were detected in both groups. Overall, the FAL index was statistically increased in the HCC-prone group (0.213) as compared to the HCC-free group (0.094; P = .044). Allelic loss at chromosomal arms 1p, 4q, 13q, 18q, and concurrent losses at more than 3 loci were confined to the HCC-prone group. In both groups, MSI was never ascertained using BAT26and TGFbIIR. In conclusion, an increased FAL index and the lack of MSI characterize the non–end-stage cirrhosis of patients undergoing HCC during follow-up. These data emphasize the role of early clonal changes in chronic liver disease, and their potential predictive significance for clinical use.
References
- 1 Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991; 338: 1356–1359.MEDLINE
- 2 Challen C, Guo K, Collier JD, Cavanagh D, Bassendine MF. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol 1992; 14: 342–346.MEDLINE
- 3 Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. p53 mutations in British patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology 1999; 117: 154–160.MEDLINE
- 4 Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997; 14: 2927–2933.MEDLINE
- 5
Piao Z,
Park C,
Park JH,
Kim H.
Allelotype analysis of hepatocellular carcinoma.
Int J Cancer
1998;
75: 29–33.MEDLINE
10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 6 Yeh SH, Chen PJ, Chen HL, Lai MY, Wang CC, Chen DS. Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas. Cancer Res 1994; 54: 4188–4192.MEDLINE
- 7 Kuroki T, Fujiwara Y, Nakamori S, Imaoka S, Kanematsu T, Nakamura Y. Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q. Br J Cancer 1995; 72: 383–385.MEDLINE
- 8 Hammond C, Jeffers L, Carr BI, Simon D. Multiple genetic alterations, 4q28, a new suppressor region, and potential gender differences in human hepatocellular carcinoma. Hepatology 1999; 29: 1479–1485.MEDLINE
- 9 Piao Z, Park C, Kim JJ, Kim H. Deletion mapping of chromosome 16q in hepatocellular carcinoma. Br J Cancer 1999; 80: 850–854.MEDLINE
- 10 Kishimoto Y, Shiota G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, Suou T, et al. Frequent loss in chromosome 8p loci in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol 1996; 122: 585–589.MEDLINE
- 11 De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995; 10: 1725–1729.MEDLINE
- 12 Ashida K, Kishimoto Y, Nakamoto K, Wada K, Shiota G, Hirooka Y, Kamisaki Y, et al. Loss of heterozygosity of the retinoblastoma gene in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol 1997; 123: 489–495.MEDLINE
- 13 Yamada T, De Souza AT, Finkelstein S, Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci U S A 1997; 94: 10351–10355.MEDLINE
- 14 Salvucci M, Lemoine A, Azoulay D, Sebagh M, Bismuth H, Reynes M, May E, et al. Frequent microsatellite instability in post hepatitis B viral cirrhosis. Oncogene 1966; 13: 2681–2685.
- 15 Karran P. Microsatellite instability and DNA mismatch repair in human cancer. Cancer Biol 1996; 7: 15–24.
- 16 Salvucci M, Lemoine A, Saffroy R, Azoulay D, Lepere B, Gaillard S, Bismuth H, et al. Microsatellite instability in European hepatocellular carcinoma. Oncogene 1999; 18: 181–187.MEDLINE
- 17 Kishimoto Y, Shiota G, Kamisaki Y, Wada K, Nakamoto K, Yamawaki M, Kotani M, et al. Loss of the tumor suppressor p53 gene at the liver cirrhosis stage in Japanese patients with hepatocellular carcinoma. Oncology 1997; 54: 304–310.MEDLINE
- 18
Furuta K,
Misao S,
Takahashi K,
Tagaya T,
Fukuzawa Y,
Ishikawa T,
Yoshioka K, et al.
Gene mutation of transforming growth factor beta1 type II receptor in hepatocellular carcinoma.
Int J Cancer
1999;
81: 851–853.MEDLINE
10.1002/(SICI)1097-0215(19990611)81:6<851::AID-IJC2>3.0.CO;2-D CAS PubMed Web of Science® Google Scholar
- 19 Wada I, Kanada H, Nomura K, Kato Y, Machinami R, Kitagawa T. Failure to detect genetic alteration of the mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene in hepatocellular carcinomas in Japan. Hepatology 1999; 29: 1718–1721.MEDLINE
- 20 Thorgeirsson SS, Teramoto T, Factor VM. Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis 1998; 18: 115–122.MEDLINE
- 21 Roncalli M, Bosari S, Marchetti A, Buttitta F, Bossi P, Graziani D, Peracchia A, et al. Cell cycle related-gene abnormalities and product expression in esophageal carcinoma. Lab Invest 1998; 78: 1049–1057.MEDLINE
- 22 Emmert-Buck MR, Vocke CD, Pozzati RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995; 55: 2959–2962.MEDLINE
- 23 Vocke CD, Pozzati RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 1996; 56: 2411–2416.MEDLINE
- 24
Kohno H,
Hiroshima K,
Toyozaki T,
Fujisawa T,
Ohwada H.
p53 mutation and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with nonsmall cell lung carcinoma.
Cancer
1999;
85: 341–347.MEDLINE
10.1002/(SICI)1097-0142(19990115)85:2<341::AID-CNCR11>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 25 Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, et al. Molecular evolution of the metaplasia-dysplasia- adenocarcinoma sequence in the esophagus. Am J Pathol 1999; 154: 965–973.MEDLINE
- 26 Tamura S, Nakamori S, Kuroki T, Sasaki Y, Furukawa H, Ishikawa O, Imaoka S, et al. Association of cumulative allelic losses with tumor aggressiveness in hepatocellular carcinoma. J Hepatol 1997; 27: 669–676.MEDLINE
- 27 Paradis V, Laurendeau I, Vidaud M, Bedossa P. Clonal analysis of macronodules in cirrhosis. Hepatology 1998; 28: 953–958.MEDLINE
- 28
Cravo M,
Lage P,
Albuquerque C,
Chaves P,
Claro I,
Gomes T,
Gaspar C, et al.
Bat 26 identifies sporadic colorectal cancers with mutator phenotype: a correlative study with clinico-pathological features and mutations in mismatch repair genes.
J Pathol
1999;
188: 252–257.MEDLINE
10.1002/(SICI)1096-9896(199907)188:3<252::AID-PATH354>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 29 Perucho M. Correspondence re: Boland CR, et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1999; 59: 249–256. Cancer Res 1998; 58: 5248–5257.MEDLINE
- 30 Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248–5257.MEDLINE
- 31 Takagi K, Esumi M, Takano S, Iwai S. Replication error frequencies in primary hepatocellular carcinoma: a comparison of solitary primary versus multiple primary cancers. Liver 1998; 18: 272–276.MEDLINE
- 32 Fox TR, McMillen PJ, Maronpot RR, Goldsworthy TL. Genomic instability, as measured by microsatellite alterations, is not associated with liver tumor development in the genetically susceptible B6C3F1 mouse. Toxicol Appl Pharmacol 1997; 143: 167–172.MEDLINE
- 33 Theise ND. Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Semin Liver Dis 1995; 15: 360–371.MEDLINE
- 34 Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F, Leandro G, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995; 108: 812–817.MEDLINE
- 35 Borzio M, Trere D, Borzio F, Ferrari AR, Bruno S, Roncalli M, Colloredo G, et al. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Pathol 1998; 51: 96–101.MEDLINE